GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ProQR Therapeutics NV (MEX:PRQR) » Definitions » Cyclically Adjusted Revenue per Share

ProQR Therapeutics NV (MEX:PRQR) Cyclically Adjusted Revenue per Share : MXN1.63 (As of Jun. 2024)


View and export this data going back to 2019. Start your Free Trial

What is ProQR Therapeutics NV Cyclically Adjusted Revenue per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

ProQR Therapeutics NV's adjusted revenue per share for the three months ended in Jun. 2024 was MXN1.522. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is MXN1.63 for the trailing ten years ended in Jun. 2024.

During the past 12 months, ProQR Therapeutics NV's average Cyclically Adjusted Revenue Growth Rate was 100.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

As of today (2024-09-24), ProQR Therapeutics NV's current stock price is MXN36.00. ProQR Therapeutics NV's Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2024 was MXN1.63. ProQR Therapeutics NV's Cyclically Adjusted PS Ratio of today is 22.09.

During the past 12 years, the highest Cyclically Adjusted PS Ratio of ProQR Therapeutics NV was 57.50. The lowest was 17.00. And the median was 30.90.


ProQR Therapeutics NV Cyclically Adjusted Revenue per Share Historical Data

The historical data trend for ProQR Therapeutics NV's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ProQR Therapeutics NV Cyclically Adjusted Revenue per Share Chart

ProQR Therapeutics NV Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - 0.82

ProQR Therapeutics NV Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.83 1.04 0.82 0.94 1.63

Competitive Comparison of ProQR Therapeutics NV's Cyclically Adjusted Revenue per Share

For the Biotechnology subindustry, ProQR Therapeutics NV's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ProQR Therapeutics NV's Cyclically Adjusted PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ProQR Therapeutics NV's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where ProQR Therapeutics NV's Cyclically Adjusted PS Ratio falls into.



ProQR Therapeutics NV Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, ProQR Therapeutics NV's adjusted Revenue per Share data for the three months ended in Jun. 2024 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Jun. 2024 (Change)*Current CPI (Jun. 2024)
=1.522/129.9100*129.9100
=1.522

Current CPI (Jun. 2024) = 129.9100.

ProQR Therapeutics NV Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201409 0.000 99.960 0.000
201412 0.000 99.050 0.000
201503 0.000 99.750 0.000
201506 0.000 100.230 0.000
201509 0.000 100.500 0.000
201512 0.000 99.730 0.000
201603 0.000 100.310 0.000
201606 0.000 100.260 0.000
201609 0.000 100.570 0.000
201612 0.000 100.710 0.000
201703 0.000 101.440 0.000
201706 0.000 101.370 0.000
201709 0.000 102.030 0.000
201712 0.000 101.970 0.000
201803 0.000 102.470 0.000
201806 0.000 103.100 0.000
201809 0.000 103.950 0.000
201812 0.000 103.970 0.000
201903 0.000 105.370 0.000
201906 0.000 105.840 0.000
201909 0.000 106.700 0.000
201912 0.000 106.800 0.000
202003 0.000 106.850 0.000
202006 0.000 107.510 0.000
202009 0.000 107.880 0.000
202012 0.000 107.850 0.000
202103 0.000 108.870 0.000
202106 0.088 109.670 0.104
202109 0.309 110.790 0.362
202112 0.072 114.010 0.082
202203 0.347 119.460 0.377
202206 0.277 119.050 0.302
202209 0.227 126.890 0.232
202212 0.205 124.940 0.213
202303 0.156 124.720 0.162
202306 0.277 125.830 0.286
202309 0.314 127.160 0.321
202312 0.748 126.450 0.768
202403 0.984 128.580 0.994
202406 1.522 129.910 1.522

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.


ProQR Therapeutics NV  (MEX:PRQR) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

ProQR Therapeutics NV's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=36.00/1.63
=22.09

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 12 years, the highest Cyclically Adjusted PS Ratio of ProQR Therapeutics NV was 57.50. The lowest was 17.00. And the median was 30.90.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


ProQR Therapeutics NV Cyclically Adjusted Revenue per Share Related Terms

Thank you for viewing the detailed overview of ProQR Therapeutics NV's Cyclically Adjusted Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


ProQR Therapeutics NV Business Description

Industry
Traded in Other Exchanges
Address
Zernikedreef 9, Leiden, ZH, NLD, 2333 CK
ProQR Therapeutics NV is a biopharmaceutical company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber's congenital amaurosis type 10 and dyastrophic epidermolysis bullosa.